Male Fertility in Spondyloarthritis: from Clinical Issues to Cytokines Milieu. A Narrative Review.
Silvia ScriffignanoFabio Massimo PerrottaEnnio LubranoPublished in: Current rheumatology reports (2024)
Rheumatological inflammatory diseases (included SpA, AS and PsA) could impair the family planning in man life, especially when diagnosed at young age. Moreover, focusing on sperm quality, it seems that a link between sperm quality impairment and a higher disease activity exist. Focusing on therapies, Tumor Necrosis Factor inhibitors showed a safety profile on human male fertility in clinical studies. Recently, a prospective study and two double-blind placebo-controlled trials assessed the impact of methotrexate and Filgotinib on semen parameters, respectively, showing a safety profile of these drugs on human semen quality. However, there are no clinical data on the impact of Interleukin (IL)17 inhibitors(i), IL12-23i and IL23i. Concerning male fertility in SpA, AS and PsA, an unmet clinical need is still present and new studies are needed to understand the association between these diseases and male fertility, and the implication of the therapies used for these diseases. This narrative review provides an overview of the available data on male fertility in patients affected by SpA, AS and PsA.
Keyphrases
- disease activity
- prostate cancer
- rheumatoid arthritis
- endothelial cells
- placebo controlled
- double blind
- systemic lupus erythematosus
- ankylosing spondylitis
- childhood cancer
- clinical trial
- radical prostatectomy
- rheumatoid arthritis patients
- squamous cell carcinoma
- electronic health record
- ejection fraction
- quality improvement
- oxidative stress
- high dose
- randomized controlled trial
- big data
- pluripotent stem cells
- phase iii
- deep learning
- rectal cancer
- machine learning
- patient reported outcomes
- radiation therapy
- middle aged
- open label
- patient reported
- peritoneal dialysis